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Several methods have been proposed to estimate the variance in disease liability explained by large sets of genetic markers. However,
current methods do not scale up well to large sample sizes. Linear mixed models require solving high-dimensional matrix equations,
and methods that use polygenic scores are very computationally intensive. Here we propose a fast analytic method that uses polygenic
scores, based on the formula for the non-centrality parameter of the association test of the score.We estimatemodel parameters from the
results of multiple polygenic score tests based onmarkers with p values in different intervals. We estimate parameters by maximum like-
lihood and use profile likelihood to compute confidence intervals. We compare various options for constructing polygenic scores, based
on nested or disjoint intervals of p values, weighted or unweighted effect sizes, and different numbers of intervals, in estimating the
variance explained by a set of markers, the proportion of markers with effects, and the genetic covariance between a pair of traits.
Our method provides nearly unbiased estimates and confidence intervals with good coverage, although estimation of the variance is
less reliable when jointly estimated with the covariance. We find that disjoint p value intervals perform better than nested intervals,
but the weighting did not affect our results. A particular advantage of our method is that it can be applied to summary statistics from
single markers, and so can be quickly applied to large consortium datasets. Our method, named AVENGEME (Additive Variance
Explained and Number of Genetic Effects Method of Estimation), is implemented in R software.Introduction
Genome-wide association studies have been successful in
identifying many variants linked to complex diseases. To
date more than 6,000 have been found in more than 500
quantitative traits and commondiseases in humans.1 How-
ever, when considering the variance explained by the
markers associated with any specific disease, there remains
a large gap to match the heritability estimates obtained
from family studies.2 This observation has spurred the
development of theories and investigations to explain the
missing heritability, including copy-number variation,3
rare variants,4 epigenetics,5 and genetic interactions.6
It has become increasingly clear that a large portion of
the missing heritability is represented on current geno-
typing products, but the associated markers are not statis-
tically significant. Several approaches have been devel-
oped to estimate the heritability explained by a set of
genetic markers that might not be individually associ-
ated. In the linear mixed model approach, the genetic
value of each individual is treated as a random effect
whose sample covariance matrix is derived from the relat-
edness matrix, which is estimated from the genotype
data.7 Solving this model gives an estimate of the addi-
tive genetic variance explained by the available geno-
types, often called the ‘‘chip heritability.’’ Variations of
this approach include multiple classes of variant with
different effect size distributions,8,9 regression of pair-
wise phenotypic correlation on genetic correlation,10
and multivariate models to estimate genetic correlation
between traits.111Department of Non-communicable Disease Epidemiology, London School of
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heritability. Here, effect sizes for allmarkers are estimated in
one sample of data, called the training sample. These effects
are then used to construct a score for each subject in a sec-
ond sample, called the target sample, as the weighted sum
of genotypes across a set of markers. Originally, association
of the score in the target sample was used to demonstrate
the presence of missing heritability among an ensemble
ofmarkers.12More recently, the strength of this association
has been used to infer the chip heritability.13,14
A further approach uses empirical Bayes methods to esti-
mate the chip heritability from the distribution of Z scores
for individual markers.15 This has the advantage of
requiring only summary statistics from standard associa-
tion analysis. Finally, a very recent method of ‘‘LD
scoring’’16 estimates the chip heritability from the correla-
tion between the marginal effect size of a marker and a
measure of its linkage disequilibrium (LD) with other
markers, also using only summary statistics.
In general, the methods using linear mixed models are
computationally expensive and require individual-level
data to calculate the genetic relatedness matrix. Further-
more, many of these methods estimate only the chip her-
itability, but it is often of interest also to estimate the pro-
portion of markers that affect a trait. This bears on the
design of association studies, because it indicates the num-
ber and effect sizes of the associated markers remaining to
be found. It is also relevant for the debate on the nature of
evolution,17,18 because if a large number of variants affect a
trait, mechanisms of selection by polygenic adaptation are
possible, acting on standing variation without requiringHygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
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new mutations.19 Methods for the estimation of the num-
ber of genes affecting a trait have been proposed since the
early 20th century, including complex segregation analysis
comparing single- and multi-locus models with or without
polygenic background,20 but only with the recent avail-
ability of dense genome-wide data has it become possible
to assess the polygenic background itself.
Linear mixed models have been extended to allow for a
proportion of variants with effects,8 but this remains
computationally demanding. Polygenic scoring has also
been used to estimate this proportion, but again with a
computationally demanding procedure that uses repeated
genome-wide simulations within a Bayesian sampling
scheme.13 On the other hand, an analyticmethod for poly-
genic scores14 estimates only one parameter among several
defined in its model; therefore, it can estimate the propor-
tion of variants with effects if the chip heritability is
assumed to be known, or vice versa. Empirical Bayes
methods are also available to estimate the proportion of
markers with effects21 but have not been adapted to jointly
estimate this proportion with the chip heritability.
Here we extend the analytic approach of Dudbridge14 to
develop a fast analytic method based on polygenic scores
for the joint estimation of chip heritability and the propor-
tion of variants affecting the trait, and we further estimate
the genetic covariance between two related traits. A partic-
ular advantage is that our method can be applied when
only summary data is available for individual markers,
and this allows our approach to be readily applied to the
increasingly large datasets that are now being made avail-
able by study consortia.Methods
Parameter Estimation: AVENGEME
We consider the model presented by Dudbridge14 in which a pair
of standardized traits Y ¼ (Y1,Y2)0 is expressed as a linear combina-
tion of m genetic effects and an error term E ¼ (E1,E2)0:
Y ¼ b0G þ E ¼
Xm
i¼1bi1Gi þ E1;
Xm
i¼1bi2Gi þ E2
0
(Equation 1)
where G is an m vector of coded genetic markers and b an m 3 2
matrix of coefficients, with E independent of G. Assuming that
in two independent samples the estimates of the genetic effects
are given, respectively, by bbi1 and bbi2, where i ¼ 1,...,m, either
set of estimates can then be used to create polygenic scoresbS1 ¼Pmi¼1bbi2Gi and bS2 ¼Pmi¼1bbi1Gi to be tested for association
with Y1 and Y2, respectively. Focusing without loss of generality
on bS2, the statistical properties of the test of association have
been described.14 In particular, the coefficient of determination
between bS2 and Y2, i.e., the variance explained by the polygenic
score in the regression of Y2 on bS2, is given by
R2
S^2 ;Y2
¼
mcov
bbi1; bi2
2
var
bbi1

varðY2Þ
;
where the terms on the right-hand side are expressed analytically
in terms of the following parameters. For study design: sampleThe Amersizes of the two samples, (n1, n2); number of variants in the marker
panel,m, assumed to be uncorrelated; p value thresholds for select-
ing a marker into the score from the training sample, (pL,pU); and
for binary traits, population prevalences (K1,K2) and case sampling
fractions (P1,P2). For genetic model: additive genetic variance in
the training sample, s21; genetic covariance between training and
testing samples, s12; and proportion of null markers with no effect
on the trait in the training sample, p01. The variance and covari-
ance are marginal over all markers, so include the null markers
with bi1 ¼ 0 or bi2 ¼ 0.
The asymptotic non-centrality parameter of the c21 test of
association between Y2 and bS2 is given by l ¼ n2R2S^2 ;Y2=ð1 R2S^2 ;Y2 Þ;
equivalently, the expectation of the Z (or t) test is
m ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðn2R2S^2 ;Y2=ð1 R
2
S^2 ;Y2
ÞÞ
q
with the sign taken from the correla-
tion between Y2 and bS2.
Binary traits are assumed to arise from a liability threshold
model, in which each subject has an unobserved trait, called the
liability, that is normally distributed in the population. Subjects
with liability greater than a fixed threshold have the trait. The
same theory then holds when either Y1 or Y2 is binary as for
when it is quantitative, assuming linear transformations between
effects on the liability scale to effects on the observed (0/1) scale,
and accounting for ascertainment in case/control studies. Specif-
ically, each effect bij on the liability scale corresponds to an effect
bij4ðtjÞðPjð1 PjÞ=Kjð1 KjÞÞ on the observed binary scale,14
where tj ¼ F1(1  Kj) with f and F the standard normal density
and cumulative distribution functions, respectively.
We aim to estimate the genetic model parameters s21, s12, and
p01 from the association test between bS2 and Y2. Previously it
was shown14 that one parameter could be estimated by solving
for the value at which l equals the observed c2 statistic. To esti-
mate multiple parameters, we now propose using association tests
of Y2 with multiple polygenic scores constructed by selecting
markers with different p value thresholds in the training data.
We then fit parameters to the observed association tests by using
maximum likelihood.
Specifically, let d1,...,dk denote a set of k intervals within the unit
interval, where k is equal to or greater than the number of param-
eters to be estimated. For each i ¼ 1,..., k, we select markers with
p values falling in di, construct the corresponding polygenic score,
and obtain its (signed) Z score (Zi) for association with Y2. The log-
likelihood for s21, s12, and p01 is then
[

s21; s12;p01
 ¼Xk
i¼1
log4

Zi  m

s21;s12;p01; di

;
where mðs21;s12;p01; diÞ is the expectation of the Z test as described
above, expressed explicitly as a function of the model parameters
given selection interval di. Maximization of this log-likelihood
yields estimates of the model parameters. Note that any of s21,
s12, and p01 could be held fixed while the other parameter(s) are
estimated.
An equivalent procedure estimates (using obvious notation) s22,
s12, and p02 by reversing the roles of the training and target sam-
ples. Furthermore, a bidirectional procedure can be used to simul-
taneously estimate up to five parameters (s21, s
2
2, s12, p01, and p02)
by fitting to the Z scores for association of both bS2 with Y2 and bS1
with Y1.
The number of estimated parameters can be reduced by
assuming that the genetic architectures are identical in the
training and testing samples. This would occur if two samplesican Journal of Human Genetics 97, 250–259, August 6, 2015 251
Table 1. Parameter Values for Studies of Four Diseases13 and
Three Studies of Schizophrenia26
RA CD MI T2D SCZ ISC SCZ PGC1 SCZ PGC2
n1 16,016 5,309 6,042 14,919 5,953 19,548 77,195
n2 12,078 6,785 4,861 4,862 5,120 5,120 5,120
m 82,390 91,388 89,808 75,912 84,882 93,093 103,125
s21 0.18 0.44 0.48 0.49 – – 0.30
p01 0.973 0.972 0.980 0.962 – – 0.95
P1 0.248 0.394 0.491 0.416 0.423 0.477 0.425
P2 0.126 0.273 0.396 0.396 0.515 0.515 0.515
K1 0.01 0.01 0.06 0.08 0.01 0.01 0.01
K2 0.01 0.01 0.06 0.08 0.01 0.01 0.01
Abbreviations are as follows: RA, rheumatoid arthritis; CD, celiac disease; MI,
myocardial infarction; T2D, type II diabetes; SCZ, schizophrenia; ISC, Interna-
tional Schizophrenia Consortium; PGC, Psychiatric Genomics Consortium.
Values of s21 and p01 for RA, CD, MI, and T2D were estimated by Stahl
et al.13 and subsequently used in our simulations. Those for SCZ are an approx-
imation based on estimates from several studies and methods (Table 5).are drawn from the same population with the same trait defini-
tions, or if one sample is randomly split into training and target
subsets. Then we can assume s21 ¼ s22 ¼ s12 and p01 ¼ p02, esti-
mating just two parameters in either unidirectional or bidirec-
tional analysis.
Ours is not a proper likelihood because the Z scores Zi corre-
sponding to the marker selection intervals are not independent.
The presence of a marker in one interval determines its presence
or absence in all other intervals, creating dependence between
the corresponding scores, but this is not reflected in our likeli-
hood. Furthermore, the bidirectional likelihood does not account
for dependence between the scores calculated in each direction.
We are therefore using a quasi-likelihood and will later use simula-
tions to investigate its sensitivity to the assumption of indepen-
dent likelihood contributions.
Maximization of the log-likelihood is complicated by con-
straints on the range of s12. Because the absolute correlation
between bi1 and bi2 must be no greater than 1, js12j%s1s2. In
the unidirectional estimation, s22 is not identified and we need
only respect that s22%1, giving the constraint js12j%s1. In the bidi-
rectional estimation, we must also consider that the absolute cor-
relation is no greater than 1 for the markers that have non-null
effects in both training and target samples. Denoting this correla-
tion as r*, the correlation over all markers as r, and the proportion
of markers with non-null effects in both samples as g % 1 
max(p01, p02), we have
r ¼ s12g
1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s21ð1 p01Þ1s22ð1 p02Þ1
q ¼ r
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃð1 p01Þð1 p02Þp
g
s12 ¼ rs1s2 ¼ r
gs1s2ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃð1 p01Þð1 p02Þp
j s12 j%ð1maxðp01;p02ÞÞs1s2ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃð1 p01Þð1 p02Þp
:
We maximize the likelihood numerically by nesting the maximi-
zation for s12 within that for the other parameters: for each pro-
posed value of s21, s
2
2, p01, and p02, we perform a univariate maxi-
mization for s12 subject to the constraint imposed by the
proposed values.
To obtain analytic confidence intervals, we use profile likeli-
hood.22 For a general scalar parameter q, its profile log-likelihood
function is [PðqÞ ¼ [ðq; bwðqÞÞwhere bwðqÞ is themaximumlikelihood
estimate of the remaining parameters in themodel given q. Because
for a regularmodel 2ð[ðbq; bwðbqÞÞ  [ðq; bwðqÞÞÞ/D c21, for the estimated
value bq we obtain a (1  a) confidence interval as the set
fq : [PðqÞR[PðbqÞ  ð1=2Þc21ð1 aÞg where c21ð1 aÞ is the 1  a
quantile point of the c21 distribution. This procedure is used to
obtain confidence intervals for each of s21, s
2
2, s12, p01, and p02.
Often it is the genetic correlation rather than the covariance be-
tween two traits that is of interest. Because the unidirectional esti-
mation does not identify s22, the correlation cannot be estimated
unless a value is assumed for s22. In the bidirectional estimation,
the correlation and its confidence interval can be obtained via pre-
viously derived formulas.23
Association tests of polygenic scores can be calculated from
summary data alone, as shown in the gtx package for R (see Web
Resources). The regression of Y2 on bS2 has coefficient
cov

Y2; bS2
var
bS2 ¼
P
cov

Y2; bb1jGj

P
var
bb1jGj
 ¼
Pbb1jbb2j varGjP bb21j varGj
z
Pbb1jbb2js22jPbb21js22j252 The American Journal of Human Genetics 97, 250–259, August 6where s22j is the sampling variance of
bb2j, assumingmarkers are un-
correlated. This is the inverse-variance weighted mean of bb2j=bb1j
and hence has sampling variance ð1=Pbb21js22j Þ. TheWald statistic,
Pbb1jbb2js22jﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP bb21js22j
q ; (Equation 2)
is then calculated from summary effect sizes and standard errors
for the individual markers. These data are frequently available
from research consortia even when access to individual-level
data is impractical.24,25
Our methods, named AVENGEME (Additive Variance Explained
and Number of Genetic Effects Method of Estimation), are imple-
mented in R software available from the authors.
Method Evaluation
To study the statistical and operating characteristics of
AVENGEME, we simulated genome-wide marker data under
various genetic models. We based our simulations on four com-
plex diseases studied by Stahl et al.,13 allowing direct comparisons
with their ABPAmethod, which is conceptually similar to ours.We
also performed simulations based on three successively larger
studies of schizophrenia.26 The study design parameters and the
genetic models used for our simulations are given in Table 1.
For each genetic model, we simulated estimated effect sizes bb1j
and bb2j independently for eachmarker, by drawing the true effects
from the bivariate normal distribution in Equation 1 and adding
independent sampling error to each effect. We then selected
markers according to their p values in the training sample and
used the summary statistic formula in Equation 2 to obtain tests
of association for each polygenic score. We verified this approach
for sample sizes up to 10K by explicitly simulating genotypes in
case and control subjects as previously described.14 In brief, inde-
pendent biallelic markers were defined with population minor
allele frequencies uniformly distributed on (0.01,0.5). Their effect
sizes were drawn from the bivariate normal distribution such that
the desired variances and covariances were attained. Allele fre-
quencies were then derived for case and control subjects and geno-
types simulated in each. Allelic odds ratios were then computed, 2015
Table 2. Application of AVENGEME to Simulated Data for Four
Genetic Models Shown in Table 1
Estimation of s21, p01 Estimation of s
2
1, p01, s12
RA CD MI T2D RA CD MI T2D
True s21 0.180 0.440 0.480 0.490 0.180 0.440 0.480 0.490
Mean bs21 0.180 0.438 0.486 0.483 0.270 0.467 0.522 0.581
SD bs21 0.019 0.035 0.050 0.034 0.312 0.325 0.335 0.332
Coverage 0.95 0.89 0.91 0.93 0.97 0.95 0.99 0.99
True p01 0.973 0.972 0.980 0.962 0.958 0.972 0.979 0.961
Mean bp01 0.972 0.972 0.979 0.961 0.968 0.972 0.979 0.957
SD bp01 0.0054 0.0046 0.0040 0.0052 0.028 0.016 0.011 0.018
Coverage 0.94 0.85 0.88 0.90 0.98 0.95 0.98 0.98
True s12 – – – – 0.180 0.440 0.480 0.490
Mean bs12 – – – – 0.190 0.442 0.491 0.509
SD bs12 – – – – 0.034 0.048 0.061 0.072
Coverage – – – – 0.98 0.93 0.94 0.993
Mean and standard deviation of parameter estimates and coverage of 95%
confidence interval are shown over 1,000 simulations. Monte Carlo error for
the mean is SD/O1000 and for coverage of 0.95 is 0.007.from the genotype counts. The results from the genotype simula-
tions were indistinguishable from those from summary statistics,
so we adopted the summary statisticmethod, which ismuch faster
and easily scales up to very large sample sizes. Note that in our sim-
ulations, markers were assumed to be independent, i.e., in linkage
equilibrium, as assumed by AVENGEME.We will later consider the
effect of LD on our method.
For the models in Table 1, we simulated 1,000 sets of polygenic
score results and estimated the genetic model parameters via the
unidirectional AVENGEME. This was done both when assuming
s21 ¼ s12 (which reflects the assumption that the two samples
have the same geneticmodel), inwhich case AVENGEME estimates
the two free parameters s21 and p01, and when allowing s
2
1ss12, in
which case AVENGEME estimates three free parameters. We evalu-
ated the accuracy from themean and SDof the parameter estimates
and the coverage of the 95% confidence intervals.
We then considered different options for constructing polygenic
scores, simulating under the design of the largest schizophrenia
study (rightmost column of Table 1) (hereafter termed ‘‘SCZ simu-
lation’’). We fixed ten thresholds (Table S1, right half) and
compared the use of disjoint to nested p value intervals with those
thresholds, with the nested intervals each having a lower limit of
0.We compared weighted scores to unweighted scores in which all
markers were given an equal weight in the direction of disease risk.
We performed 1,000 simulations and evaluated bias, precision,
and coverage as before.
Weconsidered the effectof increasing thenumberof selection in-
tervals and the sample size. Here we simulated different heritabil-
ities in the two samples: s21 ¼ 0:3, s22 ¼ 0:45,s12¼ 0.294 (giving ge-
netic correlation of 0.8), and different proportions of null markers:
p01¼0.95andp02¼0.94 (hereafter termed ‘‘bivariate simulation’’).
We compared the use of 3, 5, 10, 20, and 40 selection intervals in
sample sizes of 10K, 20K, 40K, and 80K subjects with case sampling
fractions P1¼ 0.425 and P2¼ 0.515 and disease prevalencesK1¼K2
¼0.01. This reflected the SCZPGC2studydesign, althoughbecause
that was a meta-analysis of case/control studies, the overall sam-The Amerpling fraction should be adjusted to reflect the different fractions
in each study.We did not do this here but have found that such ad-
justments have very little effect on the estimated model.
We evaluated the bidirectional AVENGEME for the simulta-
neous estimation of all five parameters. We then returned to the
SCZ simulation and applied bidirectional AVENGEME under the
constraints s21 ¼ s22 ¼ s12 and p01 ¼ p02 to compare the precision
of the bidirectional and unidirectional AVENGEME when esti-
mating only two free parameters.
Finally, we compared AVENGEME to the genomic restricted
maximum likelihood (GREML) solution of the linear mixed
model, as implemented in the popular GCTA program.27 We per-
formed the bivariate simulation with a total sample size of 10K.
GREMLwas applied on the entire sample, whereas for AVENGEME
it was split into training and testing samples each of 5K subjects.
We also compared AVENGEME to the method of So et al.,15 which
also uses summary statistics for estimation of s21 only, under the
SCZ simulation for a total sample size of 10K.Linkage Disequilbrium
The theory underlying AVENGEME assumes that markers are un-
correlated.14 This is approximately ensured in practice by pre-
filtering markers with ‘‘LD-pruning’’ algorithms that select
markers with limited pairwise correlation. Although this practice
is common for many methods that estimate chip heritability, it
might lead to under-estimation of the true chip heritability
because the selected markers might not fully tag the causal varia-
tion. Conversely, in our approach, the residual LD among the
pruned markers might lead to over-estimation of the explained
variance and under-estimation of the proportion of null markers,
because marker effects will be biased by LD with other markers.28
We therefore performed simulations on real genotype data to
assess the effect of LD pruning. We combined genotype data
from all seven case and both control samples in phase 1 of the
Wellcome Trust Case-Control Consortium (WTCCC),29 giving
genotypes for 384,845 markers on 15,769 subjects after basic
quality control (Table S2). We allocated a chip heritability of
s21 ¼ s22 ¼ s12 ¼ 0:3 among a random 5% of the markers (p01 ¼
p02¼ 0.95). We simulated a normally distributed quantitative trait
under this model, split the sample into equally sized training and
target samples, and estimated the model with AVENGEME on a
reduced marker set. We considered both a ‘‘pruning’’ algorithm,
which does not take association results into account (‘‘indep-pair-
wise’’ option in PLINK,30 window size 100, step 10), and a ‘‘clump-
ing’’ algorithm that greedily retains themost associatedmarkers in
the reduced set (‘‘clump’’ option in PLINK with index and
clumped p value thresholds of 1 and 100 marker radius). Both al-
gorithms were applied with r2 thresholds of 0.1 and 0.2, giving
reduced sets of approximately 77,000 and 102,000 markers,
respectively, on average. The simulation was repeated 1,000 times.Results
Bias and Precision
We simulated data based on the estimates for additive ge-
netic variance and proportion of null markers obtained
by Stahl et al.13 for four common diseases (Table 1). We
compared the performance of AVENGEME for these four
models with the same p value intervals as those authors
(Table S1). Results are shown in Table 2. For the estimationican Journal of Human Genetics 97, 250–259, August 6, 2015 253
Table 3. Comparison of AVENGEME Performance with Weighted
and Unweighted Score with Nested or Disjoint Intervals
Estimation of s21, p01 Estimation of s
2
1, p01, s12
Disjoint Nested Disjoint Nested
W U W U W U W U
Mean bs21 0.274 0.274 0.254 0.258 0.299 0.298 0.422 0.471
SD bs21 0.011 0.011 0.008 0.009 0.105 0.106 0.045 0.081
Coverage 0.36 0.37 0 0 0.94 0.93 0.01 0.20
Mean bp01 0.950 0.950 0.951 0.950 0.946 0.946 0.941 0.933
SD bp01 0.004 0.004 0.003 0.003 0.016 0.017 0.006 0.008
Coverage 0.93 0.93 0.80 0.78 0.95 0.94 0.37 0.14
Mean bs12 – – – – 0.281 0.280 0.289 0.309
SD bs12 – – – – 0.042 0.043 0.013 0.021
Coverage – – – – 0.91 0.91 0.69 0.85
The SCZ simulation model with s21 ¼ s12 ¼ 0:3, p01¼ 0.95 was used (see main
text for full details). Mean and standard deviation of parameter estimates and
coverage of 95% confidence interval are shown over 1,000 simulations. Monte
Carlo error for the mean is SD/O1000 and for coverage of 0.95 is 0.007. Abbre-
viations are as follows: W, weighted; U, unweighted.of two parameters only, assuming the same genetic model
in the training and target samples, our method yielded
nearly unbiased results for both s21 and p01 with small vari-
ance, suggesting that it is expected to work very well in
practice. However, the coverage was lower than 95%,
suggesting that the analytic confidence intervals are too
narrow. This might result from our assumption that the
selection intervals make independent contributions to
the likelihood. To confirm this, we directly simulated c2
statistics from the analytic non-central distributions, inde-
pendently for each selection interval, and repeated the
estimation. The confidence intervals then indeed had
appropriate coverage (Table S3), confirming that the
assumption of independent contributions from each selec-
tion interval leads to confidence intervals that are too nar-
row. Nevertheless, this effect appears to be fairly small.
In the estimation of three parameters, the estimate of s21
had some upward bias and much larger variance; p01 had
greater variance compared to the two-parameter estima-
tion, but coverage close to 95%. Inspection of individual
simulations revealed that the estimated s21 is often close
to 0 or to 1, pulling the mean estimate toward 0.5. Gener-
ally, this suggests that the variability is too large to allow
reliable estimation of s21 when estimating p01 and s12 as
well, at least at these sample sizes. The estimates for s12,
however, showed nearly unbiased estimates and small vari-
ance, suggesting that our method is reliable for estimating
the genetic covariance when it is not assumed to equal the
variance. Coverage was slightly less accurate in the estima-
tion of three parameters, but generally close to the nomi-
nal level.
We conclude that for the estimation of s21 and p01, it is
preferable for the training and target samples to be from
the same trait population and to apply AVENGEME under254 The American Journal of Human Genetics 97, 250–259, August 6the constraint s21 ¼ s12, whereas if the interest lies in the
estimation of the genetic covariance between traits, then
the unconstrained version of AVENGEME is more
appropriate.Nested Intervals and Unweighted Scores
We wondered whether the sample sizes could be a reason
for the poorer performance of the three-parameter estima-
tion; in addition, we considered the effect of the score
weighting versus an unweighted score and whether the
p value selection intervals were disjoint or nested. We
therefore simulated under a scenario with parameters
derived from a large meta-analysis of schizophrenia26
(Methods; Table 1 rightmost column). The results are
shown in Table 3. For the two-parameter estimation,
disjoint intervals had the least bias and most accurate
coverage, although its variance was slightly greater than
for nested intervals. The reduced coverage of the confi-
dence intervals for nested intervals can be ascribed to
the dependence between intervals, which is greater for
nested intervals. The bias is possibly due to the imbalance
in the sample size between training and test set (reversing
the direction of estimation led to a reduction in bias, for
example for disjoint intervals, weighted score, mean
bs21 ¼ 0:291). Similar patterns were observed when esti-
mating three parameters, with the disjoint intervals
generally showing less bias and more accurate coverage
than the nested intervals, but with slightly increased vari-
ance. The choice of weights seems to be generally neutral,
although a slight increase in variance was observed for
unweighted scores. Taken together, these results suggest
that the weighted score with disjoint selection intervals
is the most reliable and accurate approach for use with
AVENGEME.Sample Size and Number of Selection Intervals
We then performed bivariate simulations (see Methods) to
consider the effect of varying the sample size and the num-
ber of selection intervals. In Tables S4–S7, we show the per-
formance of AVENGEME in each direction. The results
confirm the poor ability to estimate s21 or s
2
2, with mean
values mostly around 0.5 and high variance reflecting
the frequent estimates of 0 or 1. This applies across all
numbers of selection intervals, but there is a reduction in
variance as the number of intervals increases and a sub-
stantial reduction in bias and variance as the sample size
increases from 10K to 80K, whereas more bias persists for
the lower genetic variance (mean bs21 ¼ 0.362 and bs22 ¼
0.444 with 40 intervals and 80K total sample size). A
similar pattern was observed for p01 and p02, although
there was much less bias in general.
For the covariance s12, the estimation again worked
well, being nearly unbiased and with low variance regard-
less of sample size and number of selection intervals. We
again observed a general trend of improved bias and preci-
sion with more selection intervals and greater sample size., 2015
Table 4. Application of AVENGEME to Normally Distributed Traits
Simulated on Real Genotypes
Pruned Clumped Independent
r2 0.1 0.2 0.1 0.2 0.1 0.2
Mean bs21 0.173 0.281 0.297 0.389 0.297 0.300
SD bs21 0.041 0.053 0.042 0.05 0.039 0.046
Mean bp01 0.559 0.579 0.900 0.879 0.949 0.931
SD bp01 0.428 0.400 0.066 0.080 0.02 0.096
Terms are as follows: pruned, markers are randomly retained in the reduced
set; clumped, most strongly associated markers are greedily retained in the
reduced set; r2, threshold on residual pairwise LD within the reduced set; inde-
pendent, results for simulated markers with no LD between any pair. True
s21 ¼ 0:3, p01 ¼ 0.95.Bidirectional Estimation
We applied the bidirectional method to the same bivariate
simulation data for total sample size of 80K. The results (Ta-
ble S8) showed consistently lower variance for each param-
eter compared to the unidirectional estimators, but with a
similar level of bias resulting in lower coverage of the con-
fidence intervals. The information gain from analyzing the
bidirectional data together is offset to some degree by the
increased number of parameters in the model. Further-
more, this analysis was considerably more time consuming
than the unidirectional analyses.
Similarly, when applying the bidirectional estimation to
data simulated under the SCZ model (Table 1, rightmost
column) and constraining s21 ¼ s22 ¼ s12 and p01 ¼ p02 in
the estimation, we obtained lower bias for s21 (mean bs21 ¼
0.286, bp01 ¼ 0.95), similar variance (SD ðbs21Þ ¼ 0.011, SD
ðbp01Þ ¼ 0.004), and greater coverage for s21 and less for
p01 ( ¼ 0.498 for s21, ¼ 0.760 for p01) compared to the uni-
directional analyses (first column of Table 3), although the
differences were very small.
We performed a sensitivity analysis to compare the per-
formance of the bidirectional estimation with different
initial parameter values for the numerical optimization
and the results were virtually unchanged, with just a slight
change in bias, variance, and coverage. A similar analysis
conducted for the complex diseases in Table 1 also revealed
that the estimate of covariance was robust to the choice of
initial parameter values.Linkage Disequilibrium
We simulated a normally distributed trait on 15,769 sub-
jects in the WTCCC (see Methods). Using reduced marker
sets with pairwise r2 constrained to <0.1 and <0.2, we
estimated s21 ¼ s22 ¼ s12 and p01 ¼ p02 when (1) the
markers were pruned without regard to their association
and (2) the markers were clumped by greedily retaining
the most strongly associated markers. Table 4 shows that
for r2 < 0.1, AVENGEME is unbiased in estimating s21
when clumping is used but has a small downward bias
in p01. Pruning, however, incurs a strong downward bias
in both s21 and p01. For r
2 < 0.2, clumping over-estimates
s21 and under-estimates p01 owing to the residual LD.The AmerPruning reduces, but does not eliminate, these biases.
These results suggest in practice using a clumping algo-
rithm with pairwise r2 < 0.1 as the least-biased approach
with AVENGEME.
Comparison with Related Methods
We analyzed our bivariate simulations for total sample size
10K using the bivariate GREML implemented in GCTA.27
The mean bs12 was 0.265 with standard deviation 0.032,
which compared to the results in Table S4 shows that in
this case the GREML estimate has greater bias but less vari-
ance than AVENGEME.
We also applied the method by So et al.15 to the SCZ
simulation (Table 1, rightmost column). Although their
method appeared unbiased in the simulation they per-
formed in which p01 ¼ p02 ¼ 0.995, in our setting it
yielded seriously biased results for s21 with a mean estimate
of 0.189 compared to the true value of 0.3.
Having established the good operating characteristics of
AVENGEME, we applied our method to some published as-
sociation results for polygenic scores. For the four diseases
from Stahl et al.13, our estimates were systematically lower
than the ones obtained by their ABPA method (Table 5),
and for s21 our confidence intervals excluded their esti-
mates. These results were surprising because the two
methods are conceptually similar, and our simulations
had shown that under themodels inferred by ABPA, AVEN-
GEME achieved nearly unbiased estimation. LD is unlikely
to affect these results because the markers were clumped to
r2 < 0.1. We speculate that the differences might arise from
ABPA’s use of prior distributions, and we return to this
point in the Discussion. Compared to results fromGREML,
our estimates for s21 were lower, with non-overlapping con-
fidence intervals, for rheumatoid arthritis and type 2 dia-
betes, whereas the results were similar for celiac disease
and myocardial infarction.
We applied AVENGEME to three waves of SCZ meta-an-
alyses (Table 5). The genetic variance s21 was similar in the
ISC and PGC1 data, but decreased in the PGC2 data. The
proportion of null markers decreased in PGC1 and PGC2
compared to ISC. This might reflect increased heterogene-
ity: as more studies contribute to the meta-analyses,
increased genetic heterogeneity could decrease the propor-
tion of null markers, whereas increased environmental
heterogeneity could decrease the genetic variance, which
on the liability scale is expressed relative to the total vari-
ance. GREML has been applied to the ISC and PGC1
data;32 for the former, the estimate is similar to ours,
whereas it is significantly lower in the latter. ABPA has
been applied to an expanded PGC1 analysis,31 yielding a
significantly higher estimate of s21 than ours.
We finally applied AVENGEME to estimate genetic
covariance between psychiatric traits by using published
summary data.33 These data included five pairs from four
disorders: schizophrenia, bipolar disorder, major depres-
sive disorder, and autistic spectrum disorder (other combi-
nations, for which only two selection intervals wereican Journal of Human Genetics 97, 250–259, August 6, 2015 255
Table 5. Genetic Model Parameters Estimated by AVENGEME, ABPA,13,31 and GREML13,32
RA CD MI T2D SCZ ISC SCZ PGC1 SCZ PGC2
AVENGEME bs21 .13 (.09–.17) .28 (.21–.35) .34 (.24–.45) .30 (.23–.37) .31 (.28–.34) .31 (.29–.33) .24 (.24–.25)
ABPA bs21 .18 (.11–.25) .44 (.34–.54) .48 (.32–.64) .49 (.39–.59) – .50 (.45–.54)a –
GREML bs21 .32 (.25–.39) .33 (.25–.41) .41 (.28–.54) .51 (.38–.64) .33 (.27–.39) .23 (.21–.25) –
AVENGEME bp01 .946 (.887–.975) .969 (.950–.982) .965 (.933–.982) .954 (.929–.971) .953 (.940–.963) .867 (.841–.887) .852(.835–.867)
ABPA bp01 .973 (.953–.993) .972 (.954–.990) .980 (.965–.995) .962 (.941–.983) – .936 (.922–.952)a –
95% confidence intervals given in parentheses, those for ABPA converted from the reported 50% credible intervals by assuming normally distributed posteriors
and those for GREML from the reported standard error by assuming normally distributed estimators.
aIncludes an additional Swedish case/control study.reported, were excluded because our method requires at
least three). The method of Dudbridge14 has previously
been shown to agree well with GREML for these data,34
but in estimating the genetic covariance it assumes that
s21 and p01 are known exactly. Here we estimated all three
parameters simultaneously. The results are presented in Ta-
ble 6 and show that the estimates from AVENGEME are of
similar magnitude to those from GREML but are consis-
tently larger and have narrower confidence intervals.
This difference might arise from LD, because here the
markers were clumped to r2 < 0.25, which according to
Table 5 might create an upward bias in AVENGEME.Discussion
The method we have proposed allows simultaneous esti-
mation of the additive variance explained by a set of ge-
netic markers, the proportion of markers affecting the trait
of interest, and the genetic covariance between two traits.
It does so by solving analytic expressions to obtain
maximum likelihood estimates and profile likelihood con-
fidence intervals and is consequently very fast. Further-
more, the polygenic score tests required by our method
can be rapidly calculated from summary statistics for indi-
vidual markers, allowing application to very large datasets
and results from published literature. Our simulations
show that ourmethod enjoys good bias and coverage prop-
erties in spite of its assumption that the tests from different
selection intervals are independent. Although we pre-
sented results only for case/control designs here, they
represent the most challenging scenarios for polygenic
modeling and we have observed results of comparable or
greater accuracy for quantitative traits (data not shown).
AVENGEME has a number of advantages compared to
currently available methods. In comparison with GREML
it can deal with very large sample sizes and obtain esti-
mates much more rapidly, and it additionally estimates
the proportion of null markers. Compared to ABPA, it
does not require Monte Carlo sampling nor simulation of
genome-wide data and is therefore much faster;
AVENGEME also extends to estimate the covariance be-
tween related traits. Compared to the method of So256 The American Journal of Human Genetics 97, 250–259, August 6et al.15 and other empirical Bayes methods, it appears to
be less biased and can simultaneously estimate up to five
model parameters. Compared to the LD-scoring approach,
it can estimate the proportion of null markers and does not
require calculation of LD between pairs of markers.
One limitation of our approach is the need for two inde-
pendent datasets, which is often not available when com-
mon controls are used; in contrast, GREML can estimate a
bivariate model from a single sample and LD scoring is
robust to overlapping samples. We assume that population
structure has been entirely adjusted for in the target sample,
and might over-estimate chip heritability if this is not the
case, whereas GREML and LD-scoring adjust for structure
explicitly in their calculations. Our method also assumes
that markers are uncorrelated. In practice this is approxi-
mately ensured by a LD-pruning step that is also commonly
conducted for othermethods.Wehave shown that if the re-
sidual LD between pruned markers is not too high, say r2 <
0.1, then AVENGEME retains its unbiased properties if a
‘‘clumping’’ algorithm is used, but can otherwise overesti-
mate the genetic variance. In contrast, LD scoring explicitly
uses LD to estimate the variance explained. The similarity
of estimates obtained by that approach to those of ours
and other current methods suggests that this problem is
currently not too severe, but asmarker densities increase to-
ward whole-genome coverage, it will become more impor-
tant to include all markers and account for LD. Our
methods can be extended to allow correlation between
markers, and this will be pursued in a subsequent paper.
A limitation is that unless very large sample sizes are used,
estimation of the chip heritability in the training sample is
unstable if it is jointly estimated with the covariance with
the testing sample. Therefore, if the variance is of particular
interest, we recommend analyzing the same trait in both
samples, either by splitting a single sample in two or by
drawing two samples from the same trait population.
Then good performance in estimating the variance can be
achieved by constraining it to equal the covariance.
The unidirectional estimation provides good estimates
in all situations we considered. The bidirectional estima-
tion can also be applied, providing a less variable estimate
than the unidirectional estimators, with a similar degree of
bias. However, the bidirectional analysis is more time, 2015
Table 6. Genetic Covariance Estimates for Five Pairs of Four
Psychiatric Traits
AVENGEME bs12 GREML bs12
BPD-SCZ 0.199 (0.186–0.209) 0.151 (0.131–0.171)
MDD-BPD 0.134 (0.120–0.148) 0.102 (0.077–0.127)
SCZ-MDD 0.165 (0.153–0.177) 0.087 (0.065–0.110)
SCZ-ASD 0.050 (0.038–0.059) 0.03 (0.008–0.052)
ASD-BPD 0.042 (0.030–0.055) 0.008 (0.017–0.033)
Abbreviations are as follows: BPD, bipolar disorder; SCZ, schizophrenia; MDD,
major depressive disorder; ASD, autistic spectrum disorder. AVENGEME esti-
mates are from bidirectional analysis. GREML confidence intervals derived
from published standard errors35 assuming normally distributed estimators.consuming than the unidirectional, and because its reduc-
tion in variance is rather small, we do not find a compel-
ling reason to prefer it to the unidirectional.
We recommend using disjoint selection intervals,
whereas the influence of the weighting seemed limited in
the situations we considered. However, the use of nested
intervals still provides good estimates if the number of in-
tervals is sufficiently large (say ten) and appears to work
well for the covariance across sample sizes, number, and
type of intervals. Nested intervals seem more appealing
for obtaining significant tests of association between poly-
genic scores and a trait of interest, and to date have been
reported more often than disjoint intervals. However, for
the estimation of the underlying genetic model, we suggest
that results for disjoint intervals should also be made avail-
able. The current fashion for using around ten intervals ap-
pears to be sufficient for obtaining accurate estimates;
although precision increases as more intervals are used,
the gains diminish rapidly beyond that number.
Our method was generally found to produce under-
coverage of confidence intervals. This is due both to some
bias in the estimation, though this was generally small,
and the assumption of independent tests from each inter-
val. We have observed that our profile likelihood intervals
closely match the empirical distribution of parameter esti-
mates in our simulations. The under-coverage is therefore
more likely to arise from the slight bias in our estimator
rather than from the calculation of its variance. Our experi-
ence is that, in this application, anapproximately valid con-
fidence interval is generally sufficient for practitioners.
AVENGEME requires numerical optimization to estimate
parameters, and this can be sensitive to the algorithm used
and the initial estimates provided. We have used the
default settings of the optim() function in R (Nelder-
Mead non-linear optimization) and in the simulations pro-
vided the true parameter values as the initial estimates.
This was to obtain, as far as possible, the ideal results
from truly maximizing the likelihood. We found that
slight variations can result from different starting values
(our default values are 0.5 for all parameters), but the con-
clusions remain the same. In practice we suggest using a
range of plausible starting values to identify the solution
with the maximum likelihood.The AmerAVENGEME is conceptually similar to ABPA,13 both
methods seeking the genetic model that best fits the
observed results of polygenic score tests using multiple se-
lection intervals. The main difference is that AVENGEME
uses analytic formulae to construct an explicit likelihood,
whereas ABPA uses approximate Bayesian computation
withMonte Carlo sampling. In the application to the com-
plex diseases in Table 1, we obtained lower estimates for all
parameters and the reason for this might be the effect of
the prior distributions used by ABPA. Their prior for p01
is uniform on the log scale and therefore heavily favors
values of p01 close to 1. On the other hand, their prior
for s21 is beta distributed on a relative scale and does not
have a natural correspondence to maximum likelihood.
Furthermore, if the true distribution of effects departs
from the assumed model (for example, as a mixture of
normal distributions8,9), then the two methods might
diverge further. Our approach might benefit from
imposing prior distributions on the parameters and per-
forming Bayesian estimation, particularly for improving
the precision of estimating s21 jointly with s12. This is a
promising subject for future work.
Our approach provides a fast and accurate method for
estimating the genetic model parameters underlying
large-scale association studies. It is particularly applicable
to summary statistics for individual markers, often made
freely available online by research consortia. Therefore, it
will greatly facilitate the estimation of genetic covariance,
especially between traits that have been studied by
different consortia and for which combined analysis of in-
dividual-level data is logistically challenging. The rapid
estimation of genetic models at arbitrarily large sample
sizes suggests that our approach will prove useful as the
sizes of consortium and biobank studies begin to approach
millions of subjects.Supplemental Data
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